4.5 Article

Real-time Interobserver Agreement in Bowel Ultrasonography for Diagnostic Assessment in Patients With Crohn's Disease: An International Multicenter Study

Journal

INFLAMMATORY BOWEL DISEASES
Volume 24, Issue 9, Pages 2001-2006

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/ibd/izy091

Keywords

inflammatory bowel disease; radiology/imaging; Crohn's disease; inflammation

Funding

  1. AbbVie
  2. Biogen
  3. Mundipharma
  4. MSD
  5. Ferring
  6. Falk Foundation
  7. Janssen
  8. Takeda
  9. UCB
  10. Falk
  11. Shire
  12. Novartis
  13. THD
  14. Allergan
  15. Alpha Wasserman
  16. Bayer
  17. Bracco
  18. Siemens
  19. Hitachi
  20. Janssen Inc.
  21. Lantheus Medical Imaging
  22. Pentax
  23. Eisai
  24. Ajinomoto
  25. Kyorin
  26. Mitsubishi Tanabe
  27. Otsuka
  28. Kyowa Hakko Kirin
  29. Zeria
  30. JIMRO
  31. Asahi Kasei Medical
  32. Pfizer
  33. Abbott Laboratories
  34. Merck
  35. Schering-Plough
  36. Centocor
  37. Elan Pharmaceuticals
  38. Procter
  39. Gamble
  40. AstraZeneca
  41. Ferring Pharmaceuticals
  42. GlaxoSmithKline
  43. Bristol-Meyers Squibb
  44. Byk Solvay
  45. Axcan
  46. Prometheus
  47. Millennium Pharmaceuticals
  48. Giuliani SpA
  49. Broad Medical Research Foundation
  50. Novo Nordisk
  51. Teva
  52. Sirtris
  53. Lycera
  54. Sofar
  55. Zambon

Ask authors/readers for more resources

Background: The unavailability of standardized parameters in bowel ultrasonography (US) commonly used in Crohn's disease (CD) and the shortage of skilled ultrasonographers are 2 limiting factors in the use of this imaging modality around the world. The aim of this study is to evaluate interobserver agreement among experienced sonographers in the evaluation of bowel US parameters in order to improve standardization in imaging reporting and interpretation. Methods: Fifteen patients with an established diagnosis of CD underwent blinded bowel US performed by 6 experienced sonographers. Prior to the evaluation, the sonographers and clinical and radiological IBD experts met to formally define the US parameters. Interobserver agreement was tested with the Quatto method (s). Results: All operators agreed on the presence/absence of CD lesions and distinguished absence of/mild activity or moderate/severe lesions in all patients. S values were moderate for bowel wall thickness (s = 0.48, P = n.s.), bowel wall pattern (s = 0.41, P = n.s.), vascularization (s = 0.52, P = n.s.), and presence of lymphnodes (s = 0.61, P = n.s.). Agreement was substantial for lesion location (s = 0.68, P = n.s.), fistula (s = 0.74, P = n.s.), phlegmon (s = 0.78, P = 0.04), and was almost perfect for abscess (s = 0.95, P = 0.02). Poor agreement was observed for mesenteric adipose tissue alteration, lesion extent, stenosis, and prestenotic dilation. Conclusions: In this study, the majority of the US parameters used in CD showed moderate/substantial agreement. The development of shared US imaging interpretation patterns among sonographers will lead to improved comparability of US results among centers and facilitate the development of multicenter studies and the spread of bowel US training, thereby allowing a wider adoption of this useful technique.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available